Skip to main content

FOSTAIR (Emerge Health Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
194 working days (255)
Active ingredients
beclometasone dipropionate; formoterol (eformoterol) fumarate dihydrate
Registration type
New Combination

FOSTAIR (solution for inhalation) is indicated in adults (18 years and older) in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids (ICS) and 'as needed' inhaled rapid-acting beta2-agonist or
  • patients already adequately controlled on both ICS and long-acting beta2-agonists (LABA).

Symptomatic treatment of adults with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Help us improve the Therapeutic Goods Administration site